Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant hepatitis B vaccine (Hansenula polymorpha) (Sinovac Biotech Ltd.)
- Development stage
- Unknown
- Lead developer
- AIM Vaccine Co.
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
RECVAX (Hanxun Rui'an) is a recombinant hepatitis B vaccine developed and marketed by Sinovac (Beijing Kexing Bioproducts). It is produced using the *Hansenula polymorpha* yeast expression system to express the hepatitis B surface antigen (HBsAg). The vaccine is indicated for the active immunization against hepatitis B virus (HBV) infection in healthy individuals, including infants, children, and adults. By presenting the HBsAg protein to the immune system, RECVAX stimulates the production of specific neutralizing antibodies (anti-HBs), providing long-term protection against HBV. It is typically administered via intramuscular injection in a three-dose regimen at 0, 1, and 6 months. The use of *Hansenula polymorpha* is noted for achieving high expression levels and stability of the HBsAg protein compared to other yeast expression systems.
- Brand names
- RECVAXHanxun Rui'an
- Other names
- recombinant hepatitis B vaccine (Hansenula polymorpha)Sinovac hepatitis B vaccine汉逊瑞安
02
Targets
HBsAg (Hepatitis B surface antigen)CD14 (Monocyte differentiation antigen CD14)
Beyond the preview
Go deeper on recombinant hepatitis B vaccine (Hansenula polymorpha) (Sinovac Biotech Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant hepatitis B vaccine (Hansenula polymorpha) (Sinovac Biotech Ltd.).